ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag disease medicine pharma fda business clinical trials

Illustration of light blue neurons with white amyloid plaques accumulating on their axons.
New Alzheimer’s Drug Slows Cognitive Decline in Clinical Trial
Dan Robitzski | Sep 28, 2022 | 2 min read
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
A gloved hand holds a tweezer and pulls a section of DNA away from a double helix
First Person Dosed in Novel Gene Editing Clinical Trial
Amanda Heidt | Jul 12, 2022 | 4 min read
The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.
FDA Approves Oral Drug for Fabry Disease
Ashley Yeager | Aug 13, 2018 | 2 min read
The medicine increases the activity of a deficient enzyme in certain patients with the condition.
New Automated Tool Monitors Clinical Trial Reporting
Diana Kwon | Feb 21, 2018 | 3 min read
The watchdog website FDAAA TrialsTracker names and shames human studies that breach the FDA’s requirements for reporting results.
a photo of the packaging for the drug Trikafta
FDA Approves New Cystic Fibrosis Drug
Shawna Williams | Oct 24, 2019 | 1 min read
The treatment, Trikafta, increases lung function in most patients with the disease—but comes with a hefty price tag.
Biotech Buys Autoimmune Firm for $7B
Kerry Grens | Jul 16, 2015 | 1 min read
Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.
Pharma Cooperates to Achieve Precision Medicine
Catherine Offord | Feb 1, 2017 | 7 min read
The challenges of adapting drug development to the age of personalized therapies encourage collaboration among industry players.
Pandemic Accelerates Trend Toward Remote Clinical Trials
Jef Akst | May 1, 2021 | 8 min read
Now more than ever before, recruiting patients for a research study doesn’t have to mean getting them to leave their homes.
The Profits of Nonprofit
Megan Scudellari | Jan 1, 2011 | 7 min read
The surprising results when drug development and altruism collide
Updated
blue and white sign for the entrance to the FDA that says U.S. Department of Health and Human Services Food and Drug Administration
Biogen’s Alzheimer’s Drug Gets FDA Approval, Mixed Reviews
Kerry Grens | Jun 7, 2021 | 2 min read
A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.

Run a Search

ADVERTISEMENT